Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | THRB | P10828 | 1/20 | 0.77 |
| ▸ | HTT | P42858 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.51 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.51 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1627567 | 1.00 | MEN1 (0.77) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL6554473 | 1.00 | MEN1 (0.77) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL11594173 | 1.00 | MEN1 (0.77) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL11593906 | 1.00 | MEN1 (0.77) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL965023 | 1.00 | MEN1 (0.77) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL15972698 | 1.00 | MEN1 (0.77) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL381638 | 1.00 | MEN1 (0.77) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL965021 | 1.00 | MEN1 (0.77) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL1627566 | 1.00 | MEN1 (0.77) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL30104751 | 1.00 | MEN1 (0.77) | MEN1THRBHTTKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 631 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743051-A1 | 3-HYDROXYPROPYLESTERS AS SOLUBILITY ENHANCERS FOR LIPOPHILIC INGREDIENTS | Symrise AG (DE) | 2026-05-20 | — | — | EP | claimed |
| US-12544333-B2 | Lipid vesicle compositions with penetration enhancing agents | DDS RESEARCH INC. (CA) | 2026-02-10 | — | — | US | claimed |
| US-12544332-B2 | Lipid vesicle compositions with penetration enhancing agents | DDS RESEARCH INC. (CA) | 2026-02-10 | — | — | US | claimed |
| US-20260033999-A1 | TOPICAL APPLICATION FOR ABSORBENT ARTICLE | PROCTER & GAMBLE (US) | 2026-02-05 | — | — | US | claimed |
| EP-4110276-B1 | COMPOSITIONS COMPRISING ALKANEDIOLS | SYMRISE AG (DE) | 2026-01-28 | — | — | EP | claimed |
| WO-2025125362-A1 | SOLID GRANULAR MATERIAL FOR THE PREPARATION OF PERSONAL CARE PRODUCTS | BASF SE (DE) | 2025-06-19 | — | — | WO | claimed |
| WO-2025094113-A1 | MOLECULAR SOLID SUSPENSIONS FOR TRANSDERMAL DRUG DELIVERY | STARTON THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | claimed |
| US-20250134828-A1 | MOLECULAR SOLID SUSPENSIONS FOR TRANSDERMAL DRUG DELIVERY | STARTON THERAPEUTICS, INC. | 2025-05-01 | — | — | US | claimed |
| US-20250043208-A1 | LUBRICIOUS SURFACES, SYSTEMS AND METHODS FOR MAKING THE SAME | LiquiGlide Inc. | 2025-02-06 | — | — | US | claimed |
| WO-2025011745-A1 | 3-HYDROXYPROPYLESTERS AS SOLUBILITY ENHANCERS FOR LIPOPHILIC INGREDIENTS | SYMRISE AG (DE) | 2025-01-16 | — | — | WO | claimed |
| WO-2022122140-A1 | COMPOSITIONS COMPRISING ONE OR MORE (BIO)-ALKANEDIOLS WITH ACTIVE INGREDIENTS | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | claimed |
| US-11291619-B2 | Water resistance sunscreen compositions | L'OREAL (FR) | 2022-04-05 | — | — | US | claimed |
| CN-114223078-A | Capsule for lithium-sulfur secondary battery and lithium-sulfur secondary battery comprising same | 株式会社LG新能源 | 2022-03-22 | — | — | CN | claimed |
| EP-3956079-A1 | LUBRICIOUS SURFACES, SYSTEMS AND METHODS FOR MAKING THE SAME | Liquiglide Inc. (US) | 2022-02-23 | — | — | EP | claimed |
| WO-2021056106-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | DDS RESEARCH INC. (CA) | 2021-04-01 | — | — | WO | claimed |
| US-20210060166-A1 | Method for the preparation of a 1,7-bis (4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione system in polysorbates for the formation of micelles in an aqueous medium aimed at the properties of the bioavailability of curcuminoids | ASTUDILLO DE LA VEGA HORACIO (MX) | 2021-03-04 | — | — | US | claimed |
| WO-2015122887-A1 | VISCOSIFIER FOR ENHANCED OIL RECOVERY | HALLIBURTON ENERGY SERVICES, INC. (US) | 2015-08-20 | — | — | WO | claimed |
| CN-1222598-C | Cleaning method for polyethylene terephtalate containers | ECOLAB INC (US) | 2005-10-12 | — | — | CN | claimed |
| WO-2000073623-A1 | BRINE VISCOSIFICATION FOR ENHANCED OIL RECOVERY | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2000-12-07 | — | — | WO | claimed |
| US-4986851-A | MIXTURE OF ORGANIC SULFATE AND PHOSPHATE DISPERSANTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-01-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260033999-A1 | TOPICAL APPLICATION FOR ABSORBENT ARTICLE | SHBG, CUTA, PGF | MEN1 1261/4885THRB 4852/4885HTT 3065/4885 |
| US-11291619-B2 | Water resistance sunscreen compositions | CUTA, DSG1, ERCC1 | MEN1 2102/4885THRB 4128/4885HTT 552/4885 |
| US-12544332-B2 | Lipid vesicle compositions with penetration enhancing agents | LIPA, CHMP4B, NPC1L1 | MEN1 4499/4885THRB 1652/4885HTT 1054/4885 |
| US-12544333-B2 | Lipid vesicle compositions with penetration enhancing agents | LIPA, CHMP4B, VAPB | MEN1 3735/4885THRB 1754/4885HTT 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.